These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22310055)

  • 1. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.
    Wilcox C; Kautto A; Steigler A; Denham JW
    Oncology; 2012; 82(1):56-8. PubMed ID: 22310055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency.
    Kim J; Vaid M; Tyldesley S; Woods R; Pickles T
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):742-50. PubMed ID: 20630664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
    Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
    Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined hormonotherapy with external beam radiotherapy in locally advanced prostate cancer: do side effects overlap the advantages?].
    Drouin SJ; Rouprêt M; Bossi A; Bolla M
    Prog Urol; 2010 Jun; 20 Suppl 3():S186-91. PubMed ID: 20620963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.
    Timilshina N; Breunis H; Alibhai SM
    J Urol; 2012 Dec; 188(6):2183-8. PubMed ID: 23083859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
    Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
    Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.